US 11,957,753 B2
Pharmaceutical formulations containing corticosteroids for topical administration
Arturo Angel, Santa Rosa, CA (US); and Gordon Dow, Greenbrae, CA (US)
Assigned to BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed by BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed on Apr. 30, 2018, as Appl. No. 15/966,367.
Application 15/966,367 is a continuation in part of application No. 14/340,367, filed on Jul. 24, 2014, granted, now 11,213,587.
Application 14/340,367 is a continuation of application No. 13/287,176, filed on Nov. 2, 2011, granted, now 8,809,307, issued on Aug. 19, 2014.
Claims priority of provisional application 61/458,339, filed on Nov. 22, 2010.
Prior Publication US 2018/0243420 A1, Aug. 30, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/14 (2017.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 9/14 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61P 17/06 (2006.01)
CPC A61K 47/14 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/127 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61P 17/06 (2018.01)] 23 Claims
 
1. A pharmaceutical composition for topical application to the skin of an individual comprising:
a liquid oil component comprising a dicarboxylic acid ester or a monocarboxylic acid ester, and a mineral oil or a light mineral oil;
a corticosteroid at a concentration of 0.03% or less, wherein the corticosteroid is selected from the group consisting of halobetasol propionate, clobetasol, betamethasone dipropionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, fluocinonide, and amcinonide, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.±2° C.; and
an aqueous component comprising water;
wherein the pharmaceutical composition does not include white petrolatum; and
wherein the pharmaceutical composition is formulated as a lotion or a cream.